secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001759425-26-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum prelim 2025 sales ~$520M, above guidance; 2026 outlook $630-650M; acquiring Bluejay for HDV
--------------------------------------------------------------------------------

- Preliminary 2025 net product sales ~$520M, exceeding upper end of guidance.
- 2026 guidance: global net sales $630M-$650M; positive cash flow from operations in 2025.
- LIVMARLI 2025 sales ~$359M (US $243M, +69% YoY); CHOLBAM/CTEXLI ~$161M (+31% YoY).
- Proposed acquisition of Bluejay Therapeutics (brelovitug for HDV) expected close late Jan 2026; $268.5M private placements.
- Pipeline: volixibat PSC topline Q2 2026; LIVMARLI EXPAND topline Q4 2026; HDV AZURE data H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000175942526000004/0001759425-26-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000175942526000004/mirm-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001759425-26-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer